Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Glatiramer acetate
Drug ID BADD_D01021
Description Glatiramer acetate consists of the acetate salts of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine with an average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively. The average molecular weight of glatiramer acetate is 5,000-9,000 daltons. It is an immunomodulator, licensed in much of the world for reduced frequency of relapses in relapsing-remitting multiple sclerosis.
Indications and Usage For reduction of the frequency of relapses in patients with Relapsing-Remitting Multiple Sclerosis.
Marketing Status Prescription; Discontinued
ATC Code L03AX13
DrugBank ID DB05259
KEGG ID D04318
MeSH ID D000068717
PubChem ID 3081884
TTD Drug ID D04CRL
NDC Product Code 0441-3642; 0378-6960; 63629-8815; 68546-317; 63629-8816; 65129-1181; 63850-4035; 55111-945; 24795-0063; 0781-3250; 59651-517; 53104-7715; 14403-0008; 0781-3234; 24795-0068; 68546-325
Synonyms Glatiramer Acetate | Acetate, Glatiramer | Copaxone | Glatiramer | TV 5010 | 5010, TV | TV5010 | TV-5010
Chemical Information
Molecular Formula C25H45N5O13
CAS Registry Number 147245-92-9
SMILES CC(C(=O)O)N.CC(=O)O.C1=CC(=CC=C1CC(C(=O)O)N)O.C(CCN)CC(C(=O)O)N.C(CC(=O)O)C(C(=O )O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Varicose vein24.10.04.001--Not Available
Vasodilatation24.03.02.003; 23.06.05.006--Not Available
Vertigo17.02.12.002; 04.04.01.003--
Visual field defect17.17.01.001; 06.02.07.003--Not Available
Visual impairment06.02.06.008--Not Available
Vomiting07.01.07.003--
Vulvovaginal candidiasis21.14.02.003; 11.03.03.005--Not Available
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Xanthoma23.03.03.047; 14.08.04.010--Not Available
Seasonal allergy10.01.04.001; 06.04.01.013; 22.04.04.008--Not Available
Brain oedema17.07.02.003; 12.01.10.010--
Lhermitte's sign17.02.06.014--Not Available
Deep vein thrombosis24.01.02.003--Not Available
Injection site discolouration23.03.03.046; 12.07.03.038; 08.02.03.038--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Lymphatic disorder01.09.01.003--Not Available
Musculoskeletal stiffness15.03.01.005--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Injection site swelling12.07.03.018; 08.02.03.017--Not Available
Affect lability19.04.01.001--Not Available
Haemorrhage24.07.01.002--Not Available
Congestive cardiomyopathy02.04.01.003--Not Available
Rectal tenesmus15.05.03.011; 07.03.03.001--Not Available
Paraesthesia oral17.02.06.008; 07.05.03.003--Not Available
Major depression19.15.01.003--Not Available
Lung neoplasm malignant22.08.01.001; 16.19.02.001--Not Available
Nuchal rigidity17.05.02.006; 15.05.04.005--Not Available
Vasodilation procedure25.03.01.001--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
The 12th Page    First    Pre   12 13    Next   Last    Total 13 Pages